<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03772041</url>
  </required_header>
  <id_info>
    <org_study_id>263-102-00003</org_study_id>
    <nct_id>NCT03772041</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Trial of OPC-61815 Injection Compared With Tolvaptan 15-mg Tablet in Patients With Congestive Heart Failure</brief_title>
  <official_title>A Multicenter, Double-blind, Randomized, Active-controlled, Parallel-group, Non-inferiority Trial to Evaluate the Efficacy and Safety of OPC-61815 Injection Compared With Tolvaptan 15-mg Tablet in Patients With Congestive Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To confirm the non-inferiority of OPC-61815 16-mg injection to tolvaptan 15-mg tablet using
      as the primary endpoint the change in body weight following 5-day intravenous administration
      of OPC-61815 16-mg injection or 5-day oral administration of tolvaptan 15-mg tablet to CHF
      patients with volume overload despite having received diuretics other than vasopressin
      antagonists
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 16, 2019</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in body weight</measure>
    <time_frame>Baseline, Day6</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of responders in Lower Limb Edema and Pulmonary Congestion</measure>
    <time_frame>Baseline, Day6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in jugular venous distension and hepatomegaly</measure>
    <time_frame>Baseline, Day6</time_frame>
    <description>Whether or not the subject has jugular venous distension will be documented, together with the vertical height (in centimeters, to 1 decimal place) from the sternal angle to the highest point of pulsation of the internal jugular vein if distension is observed. Whether or not the liver is palpable will be documented, together with the palpated width (distance from the costal arch on the right nipple line, to 1 decimal place in centimeters) if palpable. Jugular venous distension and hepatomegaly are measured by a ruler.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who achieve resolution of pulmonary rales and third cardiac sound</measure>
    <time_frame>Baseline, Day6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in New York Heart Association classification</measure>
    <time_frame>Baseline, Day6</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">288</enrollment>
  <condition>Congestive Heart Failure</condition>
  <arm_group>
    <arm_group_label>OPC-61815 injection 16 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 16 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tolvaptan tablet 15mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Once daily for 5 days tolvaptan 15-mg tablet will be orally administered, followed immediately by 1-hour intravenous administration of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OPC-61815</intervention_name>
    <description>Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 16 mg</description>
    <arm_group_label>OPC-61815 injection 16 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolvaptan Tab 15 MG</intervention_name>
    <description>Once daily for 5 days tolvaptan 15-mg tablet will be orally administered, followed immediately by 1-hour intravenous administration of placebo</description>
    <arm_group_label>Tolvaptan tablet 15mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who are currently on treatment with any of the following diuretics

               1. Loop diuretics equivalent to furosemide tablet or fine granules at a dose of 40
                  mg/day or higher

               2. Concomitant use of a loop diuretic and a thiazide diuretic (including thiazide
                  analogs) at any dose

               3. Concomitant use of a loop diuretic and an aldosterone antagonist or
                  potassium-sparing diuretic agent at any dose

          -  Patients with congestive heart failure in whom lower limb edema, pulmonary congestion,
             and/or jugular venous distension due to volume overload is present

          -  Patients who are currently hospitalized or who are able to be hospitalized during the
             trial

        Exclusion Criteria:

          -  Patients with acute heart failure

          -  Patients who are on a ventricular assist device

          -  Patients who are unable to sense thirst or who have difficulty with fluid intake
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Osamu Sato</last_name>
    <role>Study Director</role>
    <affiliation>Otsuka Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Drug Information Center</last_name>
    <phone>+81-3-6361-7315</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Saiseikai Kumamoto Hospital</name>
      <address>
        <city>Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>December 5, 2018</study_first_submitted>
  <study_first_submitted_qc>December 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2018</study_first_posted>
  <last_update_submitted>March 11, 2019</last_update_submitted>
  <last_update_submitted_qc>March 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tolvaptan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

